Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length MeCP2 across molecular and biochemical functions, with both proteins exhibiting comparable, stable expression in neuronal cells Data further validate the selection of scAAV9 and miniMeCP2 in the TSHA-102 construct and provide translational support for the Part A REVEAL Phase 1/2 clinical data in patients with Rett syndrome DALLAS, April 27, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will present new preclinical in vitro data from a head-to-head evaluation of TSHA-102 (scAAV9-mini MeCP2 ) compared to an analogous ssAAV9 construct with the full-leng
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6GlobeNewswire
- Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge? [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingGlobeNewswire
- Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (TSHA) had its price target raised by Canaccord Genuity Group Inc. from $14.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
TSHA
Earnings
- 3/19/26 - Miss
TSHA
Sec Filings
- 4/22/26 - Form ARS
- 4/22/26 - Form DEFA14A
- 4/22/26 - Form DEF
- TSHA's page on the SEC website